Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer

Molecular Cancer Research

Volumn 15, Issue 7, 2017, Pages 905-914

  Mustachio, Lisa Maria ^a   Lu, Yun ^a   Tafe, Laura J ^a   Memoli, Vincent ^a,b   Rodriguez Canales, Jaime ^c   Mino, Barbara ^c   Villalobos, Pamela Andrea ^c   Wistuba, Ignacio ^c   Katayama, Hiroyuki ^c   Hanash, Samir M ^c   Roszik, Jason ^c   Kawakami, Masanori ^c   Cho, Kwang Jin ^c   Hancock, John F ^d   Chinyengetere, Fadzai ^d   Hu, Shanhu ^a   Liu, Xi ^c   Freemantle, Sarah J ^a   Dmitrovsky, Ethan ^a,b,c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CYCLIN D1; CYCLIN E; CYCLOHEXIMIDE; DEUBIQUITINASE; DEUBIQUITINASE USP18; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERFERON STIMULATED GENE 15 PROTEIN; K RAS PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; ONCOPROTEIN; PEPTIDES AND PROTEINS; PROTEIN; PROTEIN KINASE B; REGULATOR PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEINASE; USP18 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANIMAL; CARCINOGENESIS; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE KNOCKDOWN; GENETICS; KNOCKOUT MOUSE; LUNG TUMOR; MUTATION; PATHOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MEMBRANE; CYCLIN E; CYCLOHEXIMIDE; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MICE, KNOCKOUT; MUTATION; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85021813126     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0369     Document Type: Article

References (47)

1. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011;3:1787-808.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
3. Macerecilli M, Caramella C, Faivre L, Besse B, Pianchard D, Polo V, et al. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? J Lung Cancer 2014; 83:383-8.
4. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting Ras proteins. Genes Cancer 2011;2:359-72.
5. Frezza M, Schmitt S, Dou QP. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy. Curr Top Med Chem 2011; 11:2888-905.
6. Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demi-denko E, et al. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARa and inhibits the growth of acute promye-locytic leukemia. Cancer Res 2010;70:9875-85.
7. Shah SJ, Blumen S, Pitha-Rowe I, Kitareewan S, Freemantle SJ, Feng Q, et al. UBE1L represses PML/RARa by targeting the PML domain for ISG15yla-tion. Mol Cancer Ther 2008;7:905-14.
8. Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, et al. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther 2012;11:1968-77.
9. Yuan WM, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 2011;20:362-71.
10. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc Natl Acad Sci USA 2004;101:7578-82.
11. Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci USA 2006;103:10735-40.
12. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins.JBiol Chem 2002;277:9976-81.
13. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 iso-peptidase activity. EMBO J 2006;25:2358-67.
14. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C. Deubiquiti-nases in cancer: new functions and therapeutic options. Oncogene 2012; 31:2373-88.
15. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-309.
16. Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 2006;66: 4198-207.
17. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 1988;85:9268-72.
18. Hu S, Danilov A, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, et al. CDK2 inhibition causes anaphase catastrophe in lung cancer through the cen-trosomal protein CP110. Cancer Res 2015;75:2029-38.
19. Cho KJ, Park JH, Piggott AM, Salim AA, Gorfe AA, Parton RG, et al. Staurosporines disrupt phosphatidylserine trafficking and mislocalizes ras proteins. J Biol Chem 2012;287:43573-84.
20. Appolloni A, Prior IA, Lindsay M, Parton RG, Hancock JF. H-ras but not K-rastrafficstothe plasma membrane throughtheexocyticpathway. Mol Cell Biol 2000;20:2475-87.
21. Prior IA, Muncke C, Parton RG, Hancock JF. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 2003; 160:165-70.
22. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, et al. Endomembranetraffickingofras: the CAAX motif targets proteinstothe ER and Golgi. Cell 1999;98:69-80.
23. Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004;10:7547-54.
24. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA 2007;104:4089-94.
25. To MD, Quigley DA, Mao JH, Del Rosario R, Hsu J, Hodgson G, et al. Progressivegenomic instabilityinthe FVB/Kras(LA2) mouse modelof lung cancer. Mol Cancer Res 2011;9:1339-45.
26. Ritchie KJ, Malakhov MP, Hetherington CJ, Zhou L, Little MT, Malakhova OA, et al. Dysregulation of protein modification by ISG15 results in brain cell injury. Genes Dev 2002;16:2207-12.
27. Richer E, Prendergast C, Zhang DE, Qureshi ST, Vidal SM, Malo D. N-ethyl-N-nitrosourea-induced mutation in ubiquitin-specific peptidase 18 causes hyperactivation of IFN-alphaa/b signaling and suppresses STAT4-induced IFN-gamma production, resulting in increased susceptibility to Salmonella typhimurium. J Immunol 2010;185:3593-601.
28. Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. Biochim Biophys Acta 2007;1773:1177-95.
29. Basters A, Geurink PP, Oualid FE, Ketscher L, Casutt MS, Krause E, et al. Molecular characterization of ubiquitin-specific protease 18 reveals substrate specificity for interferon-stimulated gene 15. FEBS J 2014;281:1918-28.
30. Burks J, Reed RE, Desai SD. ISGylation governs the oncogenic function of Ki-Ras in breast cancer. Oncogene 2014;33:794-803.
31. Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y. Targetingof K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1999; 1452:228-42.
32. Zimmerman G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, et al. Small molecular inhibition of the KRAS-PDEd interaction impairs onco-genic KRAS signaling. Nature 2003;497:638-42.
33. Van der Hoeven D, Cho KJ, Chiqurupati S, Parton RG, Hancock JF. Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission. Mol Cell Biol 2013;33:237-51.
34. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6.
35. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008;121:3853-7.
36. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechol 2010;2010:1-13.
37. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009;10:550-63.
38. Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 2014;28:1739-51.
39. Lopez-Alcala C, Alvarez-Moya B, Villalonga P, Calvo M, Bachs O, Agell N. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J Biol Chem 2008;283:10621-3.
40. Shukla S, Allam US, Ahsan A, Chen G, Krishnamurthy PM, Marsh K, et al. KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated b-TrCP1 degradation. Neoplasia 2014;16:115-28.
41. Tsai Y, Pestka S, Wang L, Runnels LW, Wan S, Lyu YL, et al. Interferon-b signaling contributes to Ras transformation. PLoS One 2011;6:e24291.
42. Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, et al. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer 2015;15:886.
43. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
44. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007;9:493-505.
45. Collado M, Serrano M. Senescence in tumors: evidence from mice and humans. Nat Rev Cancer 2010;10:51-7.
46. Mustachio LM, Kawakami M, Lu Y, Rodriguez-Canales J, Mino B, Behrens C, et al. The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget 2017;8:3-14.
47. Farshi P, Deshmukh RR, Nwankwo JO, Arkwright RT, Cvek B, Liu J, et al. Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin Ther Pat 2015;25:1191-208.